← Back
$RAPP All transactions

Rapport Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$63K

Shares

2,100

Price

$30

Filed

Feb 19

Insider

Name

Ceesay Abraham

Title

Chief Executive Officer

CIK

0001722140

Roles

Director Officer

Transaction Details

Transaction Date

2026-02-18

Code

S

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

20,729

Footnotes

These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. | Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Filing Info

Accession No.

0001193125-26-059886

Form Type

4

Issuer CIK

0002012593

Ceesay Abraham's History

Date Ticker Type Value
2026-02-18 RAPP $103K
2026-02-18 RAPP $68K
2026-02-18 RAPP $87K
2026-02-18 RAPP $63K
2026-02-02 RAPP A $0
2026-01-20 RAPP $152K
2026-01-20 RAPP $133K
2025-12-17 RAPP $70K
2025-12-17 RAPP $84K
2025-12-17 RAPP $19K

Other Insiders at RAPP (90d)

Insider Bought Sold Last
Ignelzi Troy A.
Chief Financial Officer
2026-02-02
Ceesay Abraham
Chief Executive Officer
$258K 2026-02-18
Third Rock Ventures V, L.P. $17.2M 2026-04-17
Sevigny Jeffrey
Chief Medical Officer
2026-02-02
Gault Cheryl
Chief Operating Officer
$282K 2026-03-30
Bredt David
Chief Scientific Officer
$247K 2026-02-19
Yeleswaram Krishnaswamy
Chief Development Officer
$1.8M 2026-04-17